Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute is a promising biopharmaceutical company with a positive outlook due to its focus on rare and metabolic diseases and its strong pipeline. Despite recent negative results from the sunRIZE study, the company has multiple ongoing trials and collaborations, and its cash position allows for continued development. With Breakthrough Therapy Designation and potential for accelerated approval, Rezolute has the potential to bring needed therapies to patients and create value for shareholders in the future.

Bears say

Rezolute is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases, such as congenital hyperinsulinism. However, a placebo effect may have contributed to the failure of its phase 3 trial for its lead candidate, RZ358. Limited data on standard of care and a small sample size also raise concerns about the drug's potential efficacy and safety. Additionally, as a clinical-stage company, Rezolute faces various risks that could impact its timeline for product development and regulatory approvals.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.